

THE TIME TO ACTe IS NOW!

Current medications prescribed for sarcoidosis were determined without adequate representation of Black Americans in clinical trials, despite their being **2.5x more likely** to have sarcoidosis than White Americans.

ADVANCE CLINICAL TRIALS FOR EQUITY

IN SARCOIDOSIS

Increasing representation of Black Americans in clinical trials and research is the pathway to developing and identifying the most effective treatments and better health outcomes for Black patients with sarcoidosis.


TAKE THE FIRST STEP

Join FSR's Patient Registry to help accelerate research by visiting:

STOPSARCOIDOSIS.ORG/ACTNOW

According to the FDA:
Only 7% of clinical trial participants are Black*

Without proper representation of Black Americans in clinical trials, therapies may not account for greater health risks, comorbidities, and higher hospitalization and mortality rates.



THERE ARE MORE SARCOIDOSIS CLINICAL TRIALS THAN EVER BEFORE, SO THE TIME TO ACTE IS NOW

BENEFITS INCLUDE...

- › more frequent communication with providers
- › increased access to medication, expert clinicians, and advanced technologies
- › monitoring regardless of insurance status

CLINICAL TRIALS & RESEARCH CAN BE AS SIMPLE AS...

- › surveys, patient registries, or interviews
- › health education programs
- › trying medications that have been FDA approved for safety in other diseases
- › a simple blood draw
- › trying new potential therapies with close oversight

Help improve care for yourself, family members impacted by sarcoidosis, and future generations! Be part of the solution.

ACTe Now. Learn How.
Visit stopsarcoidosis.org/ACTNOW

Sponsored by Boehringer Ingelheim, Kinevant Sciences, and Mallinckrodt Pharmaceuticals and made possible in part by a grant from the Chan Zuckerberg Initiative.
All sources available on the website.

IGNORE X NO MORE!



FOUNDATION FOR SARCOIDOSIS RESEARCH